IRIS Accounts Production v24.3.2.46 09414132 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh094141322023-03-31094141322024-03-31094141322023-04-012024-03-31094141322022-03-31094141322022-04-012023-03-31094141322023-03-3109414132ns15:EnglandWales2023-04-012024-03-3109414132ns14:PoundSterling2023-04-012024-03-3109414132ns10:Director12023-04-012024-03-3109414132ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3109414132ns10:SmallEntities2023-04-012024-03-3109414132ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3109414132ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3109414132ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3109414132ns10:FullAccounts2023-04-012024-03-3109414132ns10:OrdinaryShareClass12023-04-012024-03-3109414132ns10:Director22023-04-012024-03-3109414132ns10:RegisteredOffice2023-04-012024-03-3109414132ns5:CurrentFinancialInstruments2024-03-3109414132ns5:CurrentFinancialInstruments2023-03-3109414132ns5:ShareCapital2024-03-3109414132ns5:ShareCapital2023-03-3109414132ns5:RetainedEarningsAccumulatedLosses2024-03-3109414132ns5:RetainedEarningsAccumulatedLosses2023-03-3109414132ns5:FurnitureFittings2023-03-3109414132ns5:FurnitureFittings2023-04-012024-03-3109414132ns5:FurnitureFittings2024-03-3109414132ns5:FurnitureFittings2023-03-3109414132ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3109414132ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3109414132ns10:OrdinaryShareClass12024-03-31
REGISTERED NUMBER: 09414132 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

FOR

ALPHA BIOLABORATORIES CORPORATE LIMITED

ALPHA BIOLABORATORIES CORPORATE LIMITED (REGISTERED NUMBER: 09414132)

CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 March 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


ALPHA BIOLABORATORIES CORPORATE LIMITED

COMPANY INFORMATION
for the Year Ended 31 March 2024







DIRECTORS: Ms R Thomas
Mr D Thomas





REGISTERED OFFICE: Unit 14 Webster Court
Carina Park
Warrington
WA4 8WD





REGISTERED NUMBER: 09414132 (England and Wales)





ACCOUNTANTS: Xeinadin
100 Barbirolli Square
Manchester
M2 3BD

ALPHA BIOLABORATORIES CORPORATE LIMITED (REGISTERED NUMBER: 09414132)

BALANCE SHEET
31 March 2024

31.3.24 31.3.23
Notes £    £   
CURRENT ASSETS
Stocks 139,485 -
Debtors 5 3,114,189 4,185,184
Cash at bank 62,820 83,754
3,316,494 4,268,938
CREDITORS
Amounts falling due within one year 6 2,875,203 3,521,258
NET CURRENT ASSETS 441,291 747,680
TOTAL ASSETS LESS CURRENT LIABILITIES 441,291 747,680

CAPITAL AND RESERVES
Called up share capital 7 1 1
Retained earnings 441,290 747,679
SHAREHOLDERS' FUNDS 441,291 747,680

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved and authorised for issue by the Board of Directors and authorised for issue on 27 March 2025 and were signed on its behalf by:





Mr D Thomas - Director


ALPHA BIOLABORATORIES CORPORATE LIMITED (REGISTERED NUMBER: 09414132)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 March 2024


1. STATUTORY INFORMATION

Alpha Biolaboratories Corporate Limited is a private company, limited by share capital, incorporated in England and Wales, registration number 09414132. The address of the registered office and principal place of business is Unit 14 Webster Court, Carina Park, Westbrook, Warrington WA5 8WD.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover principally consists of income generated from the provision of drug and alcohol testing services which are recognised at the point the test results have been provided to the end customer.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation on tangible fixed assets is charged to the profit and loss so as to write off their value, over their estimated useful lives, using the following methods:

Fixtures and fittings25% straight line

At each balance sheet date, the Company reviews the carrying amounts of its tangible fixed assets to determine whether there is any indication that any items of property, plant and equipment have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The obligations for contributions to defined contribution scheme are recognised as an expense as incurred. The assets of the scheme are held separately from those of the company in an independent administered fund.

ALPHA BIOLABORATORIES CORPORATE LIMITED (REGISTERED NUMBER: 09414132)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 March 2024


2. ACCOUNTING POLICIES - continued

Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the trade debtors and other debtors are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortisedcost using the effective interest method unless the effect of discounting would be immaterial, inwhich case they are stated at cost.

Cash and cash equivalents
Cash and cash equivalents are represented by cash in hand and at bank.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2023 - 34 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1 April 2023 11,841
Disposals (11,841 )
At 31 March 2024 -
DEPRECIATION
At 1 April 2023 11,841
Eliminated on disposal (11,841 )
At 31 March 2024 -
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 553,486 444,688
Other debtors 2,560,703 3,740,496
3,114,189 4,185,184

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade creditors 52,844 2,511
Taxation and social security 431,602 1,045,070
Other creditors 2,390,757 2,473,677
2,875,203 3,521,258

ALPHA BIOLABORATORIES CORPORATE LIMITED (REGISTERED NUMBER: 09414132)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 March 2024


7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.24 31.3.23
value: £    £   
100 Ordinary £1.00 1 1

8. RELATED PARTY DISCLOSURES

During the year, the company paid laboratory fees to companies under common control of £830,455 (2023: £969,755).

Included within other debtors are amounts owed from companies under common control amounting to £2,568,842 (2023: £2,364,446).

Included within other creditors are amounts owed to companies under common control amounting to £2,348,271 (2023: £2,226,386).

9. ULTIMATE CONTROLLING PARTY

The ultimate controlling party are the directors of the business by virtue of their controlling interest in the business.